Abstract
ObjectivesDeveloping disease modifying therapies for Parkinson’s disease (PD) calls for outcome measurement strategies focused on characterizing early stage disease progression. We explored the psychometric evidence for using the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part II (patient motor experience of daily living) and part III (clinician motor examination) in this context.MethodsMDS-UPDRS-II and -III data were collected at screening, month 12, and month 24 from 384 early stage PD patients (diagnosis ≤ 2 years; Hoehn and Yahr stage 1/2) in the Parkinson’s Progression Markers Initiative (PPMI) study. Psychometric analysis, based on Rasch measurement theory (RMT), was performed on both the original MDS UPDRS-II and -III scales and exploratory content-driven scale structures.ResultsRMT analyses showed neither scale was well targeted to early PD. A marked floor effect appeared for most items and a clear item gap was consistently observed in very mild severity of motor signs and levels of motor impact. The original MDS-UPDRS-II and -III scales also displayed disordered thresholds (9/13 and 20/33 items, respectively), indicating response scales not functioning as expected, and misfit (5/13 and 12/33 items, respectively), flagging areas for potential improvement.ConclusionsThe MDS-UPDRS-II and -III have psychometric limitations which limits the precision of measurement of motor symptoms and impact in early PD. This can lead to insensitivity in detecting differences and clinical change. Importantly, the diagnostic psychometric evidence provided by the RMT analysis provides a clear starting point for how to improve the quantification of clinically relevant concepts to characterize the course of early PD.
Highlights
Several recent studies have grappled with the question of how to characterize the progression of Parkinson’s disease (PD)
Results indicated that Movement Disorder Society (MDS)-UPDRS-II items were mistargeted to the Parkinson Progression Markers Initiative (PPMI) patient sample
A large proportion of this early PD sample was not adequately covered by the MDS-UPDRS-II items; most item thresholds were characteristic of higher levels of the latent construct that are not relevant to the early PD patients of the PPMI sample (Fig. 4)
Summary
Several recent studies have grappled with the question of how to characterize the progression of Parkinson’s disease (PD). Studies have included estimations of the rate of progression [12] and explored the impact of laterality on the progression of disease [5]. Others have examined progression patterns in potentially different typologies of PD patients such as tremor dominant and postural instability/ gait difficulty phenotypes of PD [17] or tried to determine whether baseline PD subtypes can serve as clinically useful predictors of disease progression rate [18]. Any research on the progression of PD hinges on how we define PD severity and the methods we use to measure severity once it has been defined. The underpinning question of the measure of the severity of PD is, fundamental in this context
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
